faricimab-svoa is a vascular endothelial growth factor (VEGF) and angiopoietin 2 (Ang-2) inhibitor indicated for the treatment of patients with Neovascular (wet) Age-Related Macular Degeneration (nAMD) and Diabetic Macular Edema (DME).

read more